Agomelatine Reviews: Patient Experiences and Side Effects

Agomelatine stands out among antidepressants because patients consistently report fewer of the side effects that make other medications hard to live with, particularly sexual dysfunction, weight gain, and withdrawal symptoms on stopping. Approved in Europe and Australia but not in the United States, it works through an unusual mechanism involving melatonin receptors rather than the serotonin-boosting pathway most antidepressants rely on. That difference in mechanism translates into a genuinely different day-to-day experience for people taking it, though it comes with its own trade-off: mandatory liver monitoring.

How Agomelatine Works Differently

Most antidepressants increase serotonin, norepinephrine, or both in the brain. Agomelatine takes a completely different approach. It activates melatonin receptors (MT1 and MT2) while simultaneously blocking a specific serotonin receptor called 5-HT2C.¹ The antidepressant effect comes from the interplay between these two actions rather than from either one alone.²

For patients, this matters because so many of the side effects people dread from antidepressants are tied to elevated serotonin signaling across the body. Agomelatine does not flood the system with serotonin, so it largely sidesteps those problems. The melatonin receptor activity also means the drug has a direct hand in regulating circadian rhythms, which is why sleep benefits often appear early in treatment.

How Well Does It Actually Work for Depression?

The honest answer is that agomelatine is effective, but the evidence picture has some wrinkles. A meta-analysis that included both published and unpublished trials found that patients were about 25% more likely to respond to agomelatine than to placebo. However, the same analysis found no statistically significant advantage for full remission, meaning the complete lifting of depressive symptoms.³ That gap between response and remission is worth noting: agomelatine reliably makes depression better, but total symptom clearance is not guaranteed more often than with a sugar pill in some datasets.

When stacked against other antidepressants head-to-head, agomelatine performs roughly on par. A large Cochrane review found no meaningful difference in response or remission rates compared to SSRIs or venlafaxine.⁴ A landmark network meta-analysis published in The Lancet, which compared 21 antidepressants across hundreds of trials, placed agomelatine among the more effective and more tolerable options overall.⁵ So it holds its own against established competitors on effectiveness while earning high marks for how well people tolerate it.

The Most Common Side Effects

Data from over 3,900 patients in clinical trials give a clear picture of what to expect. The side effect profile is notably mild compared to most antidepressants:

Headache: the most common complaint, reported by about 14% of patients
Nausea: roughly 8%
Dizziness: about 6%
Dry mouth: around 4%
Diarrhea: about 3%
Drowsiness: about 3%
Fatigue: roughly 3%
Abdominal pain: about 2%
Insomnia: about 2%

Most of these were rated mild to moderate in severity.⁶ When patients describe their experience online and in observational studies, headache and nausea in the first week or two are the most frequently mentioned complaints, and both tend to settle with continued use. The overall picture is a drug that feels physically gentle relative to SSRIs and SNRIs.

Sexual Side Effects Are Strikingly Low

If there is one side effect issue that drives people away from antidepressants, it is sexual dysfunction. SSRIs and SNRIs commonly suppress libido, delay orgasm, or cause erectile difficulties, and for many patients those effects persist for as long as they take the medication. Agomelatine’s track record here is dramatically better.

In a head-to-head comparison with venlafaxine among nearly 200 sexually active patients, roughly twice as many people reported sexual deterioration with venlafaxine compared to agomelatine. When measured with a standardized sexual function scale in a larger group of about 400 depressed patients, treatment-emergent sexual dysfunction occurred in only 3% of those on agomelatine, compared to about 9% on placebo and 10% on SSRIs. A study in healthy male volunteers found that moderate or severe sexual dysfunction occurred in under 5% of those taking agomelatine versus 62% of those taking paroxetine.⁷ Those numbers are not subtle. For people who have abandoned previous antidepressants because of sexual side effects, agomelatine represents a genuine alternative.⁸

The Liver Monitoring Requirement

The trade-off that sets agomelatine apart in a less welcome way is its effect on liver enzymes. Some patients experience elevations in transaminases, the enzymes that serve as markers for liver stress. A pooled analysis of over 7,600 patients found that liver enzymes rose above three times the upper limit of normal in about 1.3% of people taking the standard 25 mg dose and about 2.5% of those on the higher 50 mg dose, compared to 0.5% on placebo.⁹ The risk is clearly dose-dependent.¹⁰

The good news is that this is nearly always reversible. In the pooled analysis, most enzyme elevations appeared within the first 12 weeks. The median time to recovery after stopping the drug was about two weeks, and in more than a third of cases the enzymes normalized even without stopping treatment, suggesting the liver adapts.⁹ No cases of acute liver failure or death from liver injury occurred in the clinical trial population. A large real-world study across four European countries found that agomelatine was not associated with higher rates of hospitalization for acute liver injury compared to citalopram.¹¹

In practice, prescribers are required to run liver function tests before starting agomelatine and then periodically during treatment, typically at around three weeks, six weeks, three months, and six months. Patients who already have elevated liver enzymes or liver disease are not prescribed the drug. This monitoring protocol is one reason some clinicians hesitate to prescribe agomelatine even where it is available: the blood tests add a logistical step that SSRIs do not require.

Sleep Benefits That Show Up Early

Because agomelatine works on melatonin receptors, its effects on sleep are among the first things patients notice. Studies show it increases the duration of deep sleep (the restorative non-REM phase) without altering REM sleep, leading to improvements in both sleep quality and continuity. In comparisons with venlafaxine, agomelatine produced earlier and greater improvements in the ability to fall asleep, with benefits apparent from the very first week of treatment.¹² Patient accounts frequently mention that sleep is the first thing to improve, sometimes within the first few nights. For someone with depression-related insomnia, that quick win can make an enormous difference in willingness to stay on the medication long enough for the full antidepressant effect to develop.

Weight and Body Composition

Weight gain is another common reason patients stop antidepressants. Mirtazapine, paroxetine, and some tricyclics are particularly notorious for it. Agomelatine is generally weight-neutral. An observational study of depressed patients with cardiovascular disease found that body weight actually decreased slightly after 12 weeks of treatment, though the change did not exceed 5% of starting weight.¹³ While that finding comes from a specific population, it is consistent with the broader clinical trial data showing no meaningful weight gain with agomelatine.

Stopping Without Withdrawal

Antidepressant discontinuation syndrome, the wave of dizziness, “brain zaps,” irritability, and flu-like feelings that can hit when you stop certain antidepressants, is one of the most feared aspects of SSRI and SNRI treatment. Agomelatine does not appear to cause it. A randomized, double-blind study directly compared what happened when patients abruptly stopped agomelatine versus paroxetine. People who stopped agomelatine experienced no more discontinuation symptoms than those who stayed on it. People who stopped paroxetine, by contrast, experienced significantly more symptoms during the first week, averaging about seven new symptoms compared to about three in the continuing group.¹⁴

A broader analysis using the WHO’s global pharmacovigilance database confirmed this pattern across real-world reporting, finding agomelatine among the antidepressants with the lowest risk of reported withdrawal syndrome.¹⁵ For people who worry about being “trapped” on a medication, this is a meaningful reassurance.

What Patients Report About Mood, Motivation, and Daily Life

A year-long observational study of agomelatine in standard French medical practice found that quality of life and daily functioning improved progressively, while the number of work days lost and underproductive days decreased over the follow-up period. About 62% of patients stayed on the drug for at least six months.¹⁶ That retention rate matters because one of the biggest obstacles in depression treatment is people quitting their medication before it has time to work or to show its full benefit.

One area where agomelatine seems to impress patients is anhedonia, the inability to feel pleasure that is often the most stubborn symptom of depression. An open-label study found that anhedonia scores dropped by more than half over eight weeks, with statistically significant improvement visible from the first week.¹⁷ A separate study confirmed significant reductions in anhedonia severity from around week three through to the trial endpoint.¹⁸ Patients often describe this as the drug making them “feel like themselves again” rather than providing a numbed-out version of feeling better, a complaint that surfaces frequently with SSRI use.

Anxiety and Beyond Depression

Agomelatine is not just an antidepressant in practice. Pooled analyses show it has a greater effect on anxiety symptoms than both placebo and several comparator antidepressants, with the benefit particularly pronounced in people whose depression comes with heavy anxiety.¹⁹ A dedicated trial in people with generalized anxiety disorder (without depression) found significant improvements on anxiety scales at both 10 mg and 25 mg doses over 12 weeks, including reductions in physical anxiety symptoms and functional impairment.²⁰ This dual action on mood and anxiety, without the sedation or cognitive blunting some people experience on benzodiazepines or high-dose SSRIs, is a frequently cited reason patients prefer agomelatine.

Staying Well Over the Long Term

For many patients, the more pressing concern than short-term side effects is whether an antidepressant keeps working and prevents relapse. In a six-month, double-blind relapse prevention trial, people who stayed on agomelatine had a relapse rate of about 22%, compared to roughly 47% for those switched to placebo.²¹ A second relapse study confirmed a twofold reduction in relapse rates sustained out to at least 10 months, with benefits holding even in patients with more severe depression.²² These numbers are comparable to relapse prevention rates seen with established antidepressants, and they counter the concern that agomelatine’s milder side-effect profile might come at the expense of sustained efficacy.

Older Adults

Depression in people over 65 is common and undertreated, partly because older adults are more vulnerable to side effects like falls from dizziness, cognitive dulling, and dangerous drug interactions. A placebo-controlled trial specifically enrolled 222 elderly patients, including 69 people aged 75 and older. Agomelatine significantly improved depression scores and response rates in this group. The response rate was about 60% with agomelatine versus 39% with placebo. Tolerability was good, with only minimal differences from placebo in adverse events.²³ The effects were even more pronounced in the subset of patients with severe depression. For older patients who struggle with the sedation or anticholinergic effects of other antidepressants, agomelatine is a credible option, though the liver monitoring applies equally here.

When Other Treatments Have Not Worked

For people with treatment-resistant depression, the evidence on agomelatine is thinner and more exploratory. A chart review study looked at combining agomelatine with bupropion in patients who had not responded to previous treatments and found promising remission rates, though the study was small and uncontrolled.²⁴ A broader observational study found that agomelatine combined with other antidepressants was effective and well tolerated in practice, though interestingly, agomelatine alone performed at least as well as the combinations.²⁵ One trial pairing agomelatine with electroconvulsive therapy found no added benefit over ECT with placebo for post-treatment relapse rates.²⁶ The combination strategy remains an area where clinical experience is ahead of controlled evidence.

Where You Can and Cannot Get It

Agomelatine is approved and marketed in Europe, Australia, and a number of other countries. It has not been approved by the U.S. FDA, which means American patients cannot get it through standard prescriptions. The FDA’s decision was related to concerns about the strength of the efficacy data in the submitted trials rather than safety problems per se. This regulatory gap frustrates patients in the U.S. who have heard about it from people in Europe or Australia, and it means that any American trying it is either obtaining it from abroad or participating in a research study.

In countries where it is available, agomelatine is typically priced higher than generic SSRIs, though a health-economic analysis found it cost-effective relative to several commonly used antidepressants when factoring in tolerability-related costs like treatment switching and lost productivity.²⁷ Generic versions have begun to enter some markets, which should bring the price down.

What Animal Research Suggests About Cognition

A less discussed but intriguing line of evidence comes from preclinical work on memory and cognition. In mice subjected to chronic stress, agomelatine blocked stress-induced deterioration in both visual and spatial memory and reversed molecular changes in the hippocampus associated with learning impairment.²⁸ These are animal findings and cannot be directly mapped to human experience, but they fit with patient reports of feeling cognitively sharper on agomelatine compared to medications that increase serotonin broadly. Some SSRIs are associated with a foggy, “cotton-head” feeling that patients describe as trading emotional pain for mental dullness. Whether agomelatine actively protects cognition in humans or simply avoids impairing it remains an open question, but it is the kind of finding that makes researchers pay attention.